PCSK9 inhibitors, e.g., the monoclonal antibodies alirocumab and evolocumab and the recently approved small-interference RNA inclisiran may add up to 40–60% average reduction in LDL-C in adults with heterozygous FH [33,34,35]. This evidence concerns the gene PCSK9 and familial hyperaldosteronism.